Display options
Cite
Burtin C, Noirot C, Scheinmann P, et al. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol. 1988;24(2):161-7doi: 10.1016/0277-5379(88)90247-7.
Burtin, C., Noirot, C., Scheinmann, P., Galoppin, L., Sabolovic, D., & Bernard, P. (1988). Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). European journal of cancer & clinical oncology, 24(2), 161-7. https://doi.org/10.1016/0277-5379(88)90247-7
Burtin, C, et al. "Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine)." European journal of cancer & clinical oncology vol. 24,2 (1988): 161-7. doi: https://doi.org/10.1016/0277-5379(88)90247-7
Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol. 1988 Feb;24(2):161-7. doi: 10.1016/0277-5379(88)90247-7. PMID: 3356203.
Copy Download .nbib Format: NLM
Share it on

Eur J Cancer Clin Oncol. 1988 Feb;24(2):161-7. doi: 10.1016/0277-5379(88)90247-7.

Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine).

European journal of cancer & clinical oncology

C Burtin, C Noirot, P Scheinmann, L Galoppin, D Sabolovic, P Bernard

Affiliations

  1. U 200, Faculté de Médecine Necker--Enfants Malades, Paris, France.

PMID: 3356203 DOI: 10.1016/0277-5379(88)90247-7

Abstract

In a randomized study 31 patients with advanced cancer disease in whom classical anticancer therapy had been abandoned received a daily combination of subcutaneous histamine and oral H2-antihistaminics. In 27 patients, treatment induced a marked clinical improvement as shown by a large rise in performance status (Karnofsky scale). Ten patients were still alive 3-14 months after initiation of treatment. Average survival in the 31 treated patients (172 +/- 113 days) was significantly longer than in 34 non-treated patients with similar advanced cancer (26 +/- 16 days, P less than 0.00001). In six treated patients, the size of liver and lung metastases decreased. Histamine was perfectly tolerated up to 4 mg/day.

Cited by

Substances

MeSH terms

Publication Types

LinkOut - more resources